In conclusion, we identified the critical role of miR-26b-5p in chronic liver injury and angiogenesis, and we explored the underlying mechanism associated with the negative regulation of miR-26b-5p on its target PDGFR-β and interaction with lncMEG3, which may open new perspectives for pharmacological treatment of liver fibrosis. This evidence concerns the gene PDGFRB and Hepatic fibrosis.